MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why JSPR Stock slipped -1.26% Today — RQD Quant Desk Flash
$0.53 -1.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Jasper Therapeutics Inc. (JSPR) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $17.7M
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JSPR)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JSPR Stock slipped -1.26% Today — RQD Quant Desk Flash
Jasper Therapeutics Inc. (JSPR) slipped -1.26% to $0.53, trading at 10% of its 52-week range ($0.32 – $2.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($0.32 – $2.42) with RSI-14 at 44.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live JSPR Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JSPR)
- ✓Walkthrough of JSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.62%📐 HORIZONTAL RANGE
2026-10-30O $0.52H $0.55L $0.51C $0.53VOL 396.0K
RES: $1.03SUP: $0.45SMA50: $0.60SMA200: $0.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on JSPR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JSPR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JSPR)
Health Care Rank #624 of 1016
⚔️ SCLX vs JSPR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JSPR vs. SCLX, PLUR, DYAI, BCDA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Jasper Therapeutics Inc. (JSPR) ranks #624 by composite RQD confidence (41/100, grade D-) and #841 by equity capitalization ($17.7M). Within this direct 5-issuer industry benchmark cohort, JSPR leads on earnings valuation at N/A trailing P/E, while JSPR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with JSPR at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JSPR
ACTIVE
Jasper Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | -1.26% | $17.7M | Benchmark Subject |
| SCLX Scilex Holding Company | D+ | 52/100 | — | 96.0% | -35.0% | -1.43% | $17.5M | /sclx-vs-jspr → |
| PLUR Pluri Inc. | D- | 39/100 | — | 49.0% | -35.0% | -2.44% | $16.1M | /plur-vs-jspr → |
| DYAI Dyadic International Inc. | E | 33/100 | — | 24.9% | -35.0% | -8.40% | $14.5M | /dyai-vs-jspr → |
| BCDA BioCardia Inc. | D | 49/100 | — | — | -35.0% | -2.26% | $14.0M | /bcda-vs-jspr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001788028In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$76, operating cash flow of -$77.2M, and free cash flow of -$77.2M (-23.3% YoY). On the balance sheet, JSPR closed FY2025 with $35.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$76 | -$77.2M | -$77.2M | $35.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$71.3M | -$62.6M | -$62.6M | $79.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$64.5M | -$52.1M | -$52.1M | — | — |
3. JSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.53 (-1.26% 1D, market cap $17.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, JSPR ranks #624 in composite RQD confidence.
How does JSPR compare to SCLX and PLUR in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCLX (Scilex Holding Company) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $17.5M) and PLUR (Pluri Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JSPR?
Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $0 in revenue, -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JSPR trading relative to its 50-day, 200-day, and 52-week technical levels?
JSPR last traded at $0.53 (-1.26% on volume of 413,083 shares), positioning the stock -11.67% below its 50-day simple moving average ($0.60) and -37.65% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.32 to $2.42, JSPR sits at the 10.0% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.60).
JSPR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is JSPR stock moving today?
Why JSPR Stock slipped -1.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.